Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Elisa Parciante
Genomic BCR-ABL1 Breakpoint Characterization by a Multi-Strategy Approach for �personalized Monitoring� of Residual Disease in Chronic Myeloid Leukemia Patients
Oncotarget
Oncology
Related publications
The Benefit of Quality Control Charts (QCC) for Routine Quantitative BCR-ABL1 Monitoring in Chronic Myeloid Leukemia
PLoS ONE
Multidisciplinary
Molecular Monitoring of Residual Disease in Chronic Myeloid Leukemia by Genomic DNA Compared With Conventional mRNA Analysis
Journal of Molecular Diagnostics
Forensic Medicine
Pathology
Molecular Medicine
Clinical and Prognostic Significance of E1a2 BCR-ABL1 Transcript Subtype in Chronic Myeloid Leukemia
Blood Cancer Journal
Oncology
Hematology
Measurable Residual Disease Testing for Personalized Treatment of Acute Myeloid Leukemia
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
Immunology
Allergy
Microbiology
Medicine
Forensic Medicine
Pathology
Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia
Molecular Therapy - Nucleic Acids
Drug Discovery
Molecular Medicine
Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia
Cancer
Cancer Research
Oncology
The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients With Chronic Myeloid Leukemia
Cancer
Cancer Research
Oncology
Requirement of SRC Kinases Lyn, HCK and FGR for BCR-ABL1-induced B-Lymphoblastic Leukemia but Not Chronic Myeloid Leukemia
Nature Genetics
Genetics
